Chimerix Starts Multi-Dose Trial for Smallpox Infection
Chimerix has initiated a multi-dose trial with its lead drug candidate, CMX001, an oral treatment for smallpox infection. This trial will study the pharmacokinetics and safety of three doses of the drug given to healthy volunteers.
Chimerix has previously demonstrated that single doses of CMX001 provided excellent drug exposure and were well tolerated in healthy volunteers. CMX001 is being developed for smallpox under a licensing agreement with Gilead Sciences. The work is partially funded by a $36.1 million grant awarded to the company by the National Institutes of Allergy and Infectious Disease.
George Painter, president and CEO of Chimerix, said: “In addition to smallpox, we believe that CMX001 has great potential in treating other serious infections such as human papillomavirus and cytomegalovirus.”